Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Nicole Cichanowitz
Clinical Efficacy or Tildrakizumab in Patients With Chronic Plaque Psoriasis Over 2 Years of Treatment: Results From Long-Term Extensions to 2 Phase 3 Clinical Studies
SKIN The Journal of Cutaneous Medicine
Related publications
Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study
Journal of the American Academy of Dermatology
Dermatology
Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study
British Journal of Dermatology
Dermatology
Medicine
Tildrakizumab for the Treatment of Plaque Psoriasis in Adults
Prescriber
Pharmacology
Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies
Headache
Neurology
Long-Term Treatment Adherence to the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Alirocumab in 6 ODYSSEY Phase III Clinical Studies With Treatment Duration of 1 to 2 Years
Journal of Clinical Lipidology
Internal Medicine
Nutrition
Cardiology
Endocrinology
Cardiovascular Medicine
Dietetics
Metabolism
Diabetes
Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study
Journal of the American Academy of Dermatology
Dermatology
Long-Term Safety of Adalimumab in Adult Patients With Plaque Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Long-Term Efficacy and Safety of Brodalumab in the Treatment of Psoriasis: 120-Week Results From the Randomized, Double-Blind, Placebo- And Active Comparator–controlled Phase 3 AMAGINE-2 Trial
Journal of the American Academy of Dermatology
Dermatology
